Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Accreditation Matters Conference 2026
15 slides from Rhythm Biosciences's conference presentation, Jul 7, 2026
Slide 1: From Innovation to Clinical Impact: The Strategic Role of NATA Accreditation
For personal use only From Innovation to Clinical Impact: The Strategic Role of NATA Accreditation ACCREDITATION MATTERS CONFERENCE 7TH JULY 2026
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, rep
Slide 3: Today's Agenda
Today’s Agenda From scientific discovery to patient impact: how accreditation transforms innovation into clinical adoption. Scope and Scale of the IVD Industry For personal use only 01 Patient impact and the economic value of the Australian pathology market Cancer Diagnostics Innovation: Saving live
Slide 4: What is the In Vitro Diagnostic Industry
What is the In Vitro Diagnostic Industry Providing insight into health to support clinical practice IVD spans the full clinical journey: For personal use only In Vitro (Latin: "in glass") — tests performed on biological samples outside the living body: blood, urine, tissue, swabs. Screening & preven
Slide 5: The Seven Pillars of Clinical Testing
The Seven Pillars of Clinical Testing MBS pathology groups P1–P9 map to these core technology domains For personal use only 1 2 3 4 Clinical Chemistry Haematology Immunodiagnostics Molecular Diagnostics Metabolites, enzymes, Full blood counts, coagulation, Hormone assays, cardiac PCR, NGS — pathogen
Slide 6: Australia's IVD Industry at a Glance
Australia’s IVD Industry at a Glance For personal use only ~0.5bn 67% AUD ~$6B pathology & diagnostic services of all Australians IVD product market size per year (2022–23) had at least one pathology in Australia (2024) Medicare 30% of total test in 2022–23 Growing ~5–6% per year AIHW 2024 AIHW 2024
Slide 7: Why Diagnostic Innovation Matters
Why Diagnostic Innovation Matters: Continual improvement on the ability to Predict, Prevent and Personalise Clinical Impact Economic Impact For personal use only per person per year — Australia's Earlier detection = better survival. For most cancers, stage I ~$190 entire MBS pathology spend detectio
Slide 8: Colorectal Cancer Case Study: Early detection leads to better outcomes
Colorectal Cancer Case Study: Early detection leads to better outcomes For personal use only 15,500+ new colorectal cancer cases diagnosed every year in Australia >50% Diagnosed as late-stage disease – Stages III or IV 10% 5-year survival rate when diagnosed at Stage IV Earlier detection significant
Slide 9: Detecting Cancer Earlier
Detecting Cancer Earlier Rhythm Biosciences is an ASX listing company For personal use only building precision diagnostics platform focused on earlier cancer detection, risk assessment and improve patient outcomes. Non-invasive blood-based bowel cancer detection test Assessing cancer risk before sym
Slide 10: The Patient Ecosystem
The Patient Ecosystem Rhythm is building a scalable precision diagnostics ecosystem across the cancer care pathway. For personal use only Y N E R Risk Assessment Disease Screening U O J MONITORING AND Genomic cancer risk Blood-based cancer detection MINIMAL RESIDUAL T RISK ASSESSMENT assessment DISE
Slide 11: What Does It Take for a Diagnostic to Reach Clinical Practice?
What Does It Take for a Diagnostic to Reach Clinical Practice? Four elements that turn scientific innovation into clinical adoption For personal use only 1. Clinical Evidence 2. Quality & 3. Clinical Logistics 4. Commercial • Demonstrates Accreditation • Sample collection Readiness analytical and cl
Slide 12: Regulatory Oversight is a Growth Driver
Regulatory Oversight is a Growth Driver Ensuring the IVD industry provides safe and effective products and services For personal use only False Positives False Negatives Unnecessary surgery, chemotherapy, and Missed diagnoses allowing disease to progress psychological harm from incorrect diagnoses.
Slide 13: Balancing the Demands facing an Emerging Business
Balancing the Demands facing an Emerging Business Embracing Regulatory Approval: worthwhile hurdle for innovative businesses Emerging businesses are resource constrained Accreditation enables market access For personal use only ➢ >400 Domestic Emerging Medtech Accreditation builds the trust that can
Slide 14: How Accreditation Enabled Commercialisation
How Accreditation Enabled Commercialisation Rhythm's journey confirms accreditation transforms validated science into clinical adoption. For personal use only Dec. 2024 Oct. 2025 Dec. 2025 March 2026 ISO 15189:2022 NATA ISO 15189:2012 ColoSTAT: First Accredited ColoSTAT Assessment Accreditation Comm
Slide 15: Thank you!
For personal use only Thank you! David Atkins, PhD CEO & MD david.atkins@rhythmbio.com www.rhythmbio.com Rhythm Biosciences An ASX Life Sciences Growth Opportunity (ASX:RHY)
Rhythm Biosciences — Accreditation Matters Conference 2026 on 6ix